Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:TARO

Taro Pharmaceutical Industries (TARO) Stock Price, News & Analysis

Taro Pharmaceutical Industries logo

About Taro Pharmaceutical Industries Stock (NYSE:TARO)

Advanced Chart

Key Stats

Today's Range
$42.97
$42.97
50-Day Range
$42.20
$42.99
52-Week Range
$32.67
$45.76
Volume
N/A
Average Volume
45,199 shs
Market Capitalization
$1.62 billion
P/E Ratio
29.84
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TARO Stock News Headlines

Leaked Gov’t Memo Reveals $100 Trillion Deadline
Only Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, and the deadline is fast-approaching. A new federal plan could legally unlock $100 trillion in U.S. resources... and one $10 stock could lead the charge. Former hedge fund manager Whitney Tilson explains how to act now, before this hits the headlines.tc pixel
See More Headlines

TARO Stock Analysis - Frequently Asked Questions

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) released its quarterly earnings results on Thursday, October, 28th. The company reported $0.66 EPS for the quarter, missing the consensus estimate of $1.02 by $0.36. The company earned $131.99 million during the quarter, compared to analysts' expectations of $153.23 million. Taro Pharmaceutical Industries had a trailing twelve-month return on equity of 3.75% and a net margin of 8.56%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Taro Pharmaceutical Industries investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
10/28/2021
Today
9/02/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSE:TARO
CIK
906338
Employees
1,554
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$1.44
Trailing P/E Ratio
29.84
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$53.87 million
Net Margins
8.56%
Pretax Margin
13.14%
Return on Equity
3.75%
Return on Assets
3.09%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.61
Quick Ratio
3.04

Sales & Book Value

Annual Sales
$629.18 million
Price / Sales
2.57
Cash Flow
$2.38 per share
Price / Cash Flow
18.03
Book Value
$47.70 per share
Price / Book
0.90

Miscellaneous

Outstanding Shares
37,590,000
Free Float
32,400,000
Market Cap
$1.62 billion
Optionable
Optionable
Beta
0.56
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NYSE:TARO) was last updated on 9/2/2025 by MarketBeat.com Staff
From Our Partners